<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> failing to achieve glycemic control with maximally effective <z:chebi fb="0" ids="6801">metformin</z:chebi> doses </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A triple-blind, placebo-controlled, 30-week study at 82 U.S. sites was performed with 336 randomized patients </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 272 patients completed the study </plain></SENT>
<SENT sid="3" pm="."><plain>The intent-to-treat population baseline was 53 +/- 10 years with BMI of 34.2 +/- 5.9 kg/m(2) and HbA(1c) of 8.2 +/- 1.1% </plain></SENT>
<SENT sid="4" pm="."><plain>After 4 weeks of placebo, subjects self-administered 5 microg exenatide or placebo subcutaneously twice daily for 4 weeks followed by 5 or 10 microg exenatide, or placebo subcutaneously twice daily for 26 weeks </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects continued <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: At week 30, HbA(1c) changes from baseline +/- SE for each group were -0.78 +/- 0.10% (10 microg), -0.40 +/- 0.11% (5 microg), and +0.08 +/- 0.10% (placebo; intent to treat; adjusted P &lt; 0.002) </plain></SENT>
<SENT sid="7" pm="."><plain>Of evaluable subjects, 46% (10 microg), 32% (5 microg), and 13% (placebo) achieved HbA(1c) &lt; or =7% (P &lt; 0.01 vs. placebo) </plain></SENT>
<SENT sid="8" pm="."><plain>Exenatide-treated subjects displayed progressive dose-dependent <z:hpo ids='HP_0001824'>weight loss</z:hpo> (-2.8 +/- 0.5 kg [10 microg], -1.6 +/- 0.4 kg [5 microg]; P &lt; 0.001 vs. placebo) </plain></SENT>
<SENT sid="9" pm="."><plain>The most frequent adverse events were gastrointestinal in nature and generally mild to moderate </plain></SENT>
<SENT sid="10" pm="."><plain>Incidence of mild to moderate <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> was low and similar across treatment arms, with no severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Exenatide was generally well tolerated and reduced HbA(1c) with no <z:mp ids='MP_0005456'>weight gain</z:mp> and no increased incidence of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> failing to achieve glycemic control with <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
</text></document>